Eli Lilly recently won its third straight trial over the withdrawal risks of its antidepressant Cymbalta, persuading a federal jury that warnings on the drug were adequate. Defense attorneys say this key finding gives the drugmaker an edge in an upcoming fight with plaintiffs trying to consolidate dozens of similar suits.
Litigation partner William Hoffman weighed in on Lilly's recent successes for Law360:
"From my perspective watching this litigation, this company has a strong defense that's being well-presented, that there is strong labeling for this product and that it's giving them the upper hand with judges considering summary judgment motions and at trial. That's going to weigh heavily on the JPML panel, since it has already rejected an earlier consolidation petition."
Also of Interest
- And Now A Word From The Panel: MDL Venue Choices November 30, 2016 • Articles
- Patrolmen’s Benevolent Association Honors Waks November 17, 2016 • Recognitions
- Second Circuit Expands Split on Nominative Fair Use November 16, 2016 • Articles
- JUVE Handbuch Recommends Frankfurt Office and Lawyers November 14, 2016 • Recognitions
- Chambers UK 2017 Recognizes London Partners and Aviation Finance Practice November 7, 2016 • Recognitions
- Kaye Scholer Advises Biohaven on Oversubscribed Private Financing November 4, 2016 • Client Successes
- Lattanzio Receives NYSBA Pro Bono Award November 3, 2016 • Recognitions
- US News–Best Lawyers Recognizes 32 Kaye Scholer Practices and 41 Lawyers November 1, 2016 • Recognitions
- Kaye Scholer Succeeds on Behalf of Term Loan Lenders in Defeating Confirmation... October 31, 2016 • Client Successes